Komori

Financial Results Presentation for the Third Quarter of the Fiscal Year Ending December 2026

Results presentationNine months, FY ending Dec 2026Published 2026-11-17 16:00

Based on progress in research and development through the third quarter and cost controls, the full-year earnings forecast for the fiscal year ending December 2026 was revised downward. Selling, general and administrative expenses are ¥426 million below the initial forecast, and the forecasts for operating loss and net loss have also been reduced.

In short

Forecast raised
  • The development pipelines are generally progressing as planned, and KP2011 is being prepared for the domestic Phase 3 trial.
  • For the nine months through the third quarter, there was no revenue, while selling, general and administrative expenses were ¥765 million, operating loss was ¥765 million and net loss for the quarter was ¥847 million.
  • The full-year forecasts for selling, general and administrative expenses and losses were revised based on progress in research and development and cost controls.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Operating profit

−¥0.8bnloss widenedvs a year earlier
9M FY25/12−¥0.7bn9M FY26/12−¥0.8bn
FY24/12FY25/12FY26/12 · this year-1-1-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲▼this yearvs same quarter last yearlast yearnew forecast-0.3 a quarterold forecast-0.8 a quarter
Operating profit by quarter
Period¥bn
FY24/12 Q1-0.2
FY24/12 Q2-0.2
FY24/12 Q3-0.2
FY24/12 Q4-0.2
FY25/12 Q1-0.2
FY25/12 Q2-0.2
FY25/12 Q3-0.2
FY25/12 Q4-0.2
FY26/12 Q1-0.2
FY26/12 Q2-0.2
FY26/12 Q3-0.3
last year -0.9
was -1.5
now -1.1
Full-year forecast, ¥bnloss narrowed vs the old forecast
Old and new forecast from the company's results releases
Why

Research and development expenses increased from the same period of the previous year but remained below the initial assumptions.

各開発パイプラインは全般的に計画通り進捗。研究開発費は前年同期比で増加したものの、期初の想定を下回って推移。
The development pipelines are generally progressing as planned. Although research and development expenses increased year on year, they remained below the initial assumptions.
Forecast

The full-year earnings forecast was revised based on actual results through the third quarter.

第3四半期までの実績を踏まえ、通期業績予想を修正(「2026年12月期 通期見通し」参照)。
The full-year earnings forecast was revised based on actual results through the third quarter (see “Full-Year Outlook for the Fiscal Year Ending December 2026”).

Net profit

−¥0.8bnloss widenedvs a year earlier
9M FY25/12−¥0.7bn9M FY26/12−¥0.8bn
FY24/12FY25/12FY26/12 · this year-1-1-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲▼this yearvs same quarter last yearlast yearnew forecast-0.3 a quarterold forecast-0.8 a quarter
Net profit by quarter
Period¥bn
FY24/12 Q1-0.2
FY24/12 Q2-0.2
FY24/12 Q3-0.2
FY24/12 Q4-0.2
FY25/12 Q1-0.2
FY25/12 Q2-0.2
FY25/12 Q3-0.2
FY25/12 Q4-0.3
FY26/12 Q1-0.3
FY26/12 Q2-0.2
FY26/12 Q3-0.4
last year -1.0
was -1.6
now -1.2
Full-year forecast, ¥bnloss narrowed vs the old forecast
Old and new forecast from the company's results releases
Why

Net loss for the quarter includes an impairment loss of ¥61 million.

減損損失61百万円を計上
Recorded an impairment loss of ¥61 million
Forecast

The full-year forecast for net loss was revised from ¥1,616 million to ¥1,192 million.

Their own numbers

figures this company chose to report, a year ago against now
Number of employees
21 people

The number of employees was 21 as of 30 September 2026.

Period during which disease progression was delayed in the ALS clinical trial
27.9 Weekly

The KP2011 clinical trial indicated the potential to delay disease progression by 27.9 weeks.

Number of patients with improved motor function among those with complete spinal cord injury
2 people

Two patients showed improved motor function in the clinical study.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

New initiatives

what they said they're starting
  • A sustained-release granule formulation was newly developed for KP2011 to improve patient convenience and quality of life.
  • For KP8011, the company is proceeding with the transfer of technology to Nikon Cell Innovation and establishing a manufacturing system for cells for company-sponsored clinical trials.
  • The company was selected for AMED’s Program to Accelerate the Realization of Regenerative, Cellular and Gene Therapies and joined the program as a collaborating company.
  • The company is considering launching multiple new central nervous system development pipelines using disease-specific iPS cells.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed

Overheads (selling and admin costs): ¥765.0m

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-141.6%
profit earned on shareholders' money
−85.2 pts on last year
-144%-87%-30%FY24/12FY25/12FY26/12FY24/12: -31.6%FY25/12: -56.4%FY26/12: -141.6% (forecast)-141.6%
Return on equity
Period%
FY24/12-31.6
FY25/12-56.4
FY26/12-141.6
Equity ratio18.8%
how much of the balance sheet is owned outright
−24.3 pts on last year
17%58%98%FY23/12FY24/12FY25/12FY26/12FY23/12: 93.7%FY24/12: 96.0%FY25/12: 43.1%FY26/12: 18.8%18.8%
Equity ratio
Period%
FY23/1293.7
FY24/1296.0
FY25/1243.1
FY26/1218.8

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

How they rate themselves against plan

the company's own grade for the period, next to the numbers
What they said
In line with plan

The company explained that the development pipelines are generally progressing as planned.

各開発パイプラインは全般的に計画通り進捗。
The development pipelines are generally progressing as planned.

Headcount

people against what they produce
21peopleas of 2026/09

Market size and share

square area = market size · a year ago outlined, now filled
ALS—North America
Market size is an approximate figure calculated by multiplying the estimated drug price by the number of patients.
market
¥825.0bn
ALS—Europe
Market size is an approximate figure calculated by multiplying the estimated drug price by the number of patients.
market
¥120.0bn
ALS—China
Market size is an approximate figure calculated by multiplying the estimated drug price by the number of patients.
market
¥100.0bn
ALS—India
Market size is an approximate figure calculated by multiplying the estimated drug price by the number of patients.
market
¥255.0bn
ALS—Japan
Market size is an approximate figure calculated by multiplying the estimated drug price by the number of patients.
market
¥25.0bn
HD—North America
Market size is an estimate.
market
¥315.0bn
FTD—Japan
Market size is an estimate.
market
¥30.0bn

The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.

Not mentioned in this deck

13
By businessWhat movedCapital spendingShare buybackDividendForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countInvestor Q&A
Financial Results Presentation for the Third Quarter of the Fiscal Year Ending December 2026 | K Pharma,Inc. (4896) timely disclosure | Komori